Utilizing Theranostics & Quantitive Systems Pharmacology to Enhance Translatability of Pre-Targeted ADC Therapies - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Utilizing Theranostics & Quantitive Systems Pharmacology to Enhance Translatability of Pre-Targeted ADC Therapies

12:00 pm - Wednesday 14th October 2026

Discussing the importance of QSP modeling to determine translation of ADC dosing paradigms between animal and human studies
Leveraging theranostics to better determine efficacy and safety of ADCs in the clinic
Using PDX models to explore relationships between antigen expression level and efficacy

Speakers:

Travis Biechele

Travis Biechele

Chief Scientific Officer

Shasqi Inc.